Virtu Financial LLC Makes New $64,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)

Virtu Financial LLC acquired a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,309 shares of the company’s stock, valued at approximately $64,000.

Other large investors have also modified their holdings of the company. Barclays PLC lifted its holdings in shares of Inozyme Pharma by 261.4% during the third quarter. Barclays PLC now owns 76,730 shares of the company’s stock valued at $401,000 after purchasing an additional 55,497 shares during the last quarter. Geode Capital Management LLC raised its holdings in Inozyme Pharma by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock worth $6,126,000 after buying an additional 19,499 shares during the period. Jane Street Group LLC lifted its stake in Inozyme Pharma by 7.5% during the third quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock valued at $259,000 after buying an additional 3,443 shares in the last quarter. Wellington Management Group LLP lifted its stake in Inozyme Pharma by 11.9% during the third quarter. Wellington Management Group LLP now owns 260,719 shares of the company’s stock valued at $1,364,000 after buying an additional 27,739 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Inozyme Pharma by 5.0% in the third quarter. State Street Corp now owns 1,050,420 shares of the company’s stock worth $5,494,000 after buying an additional 50,386 shares during the period. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Price Performance

INZY opened at $2.99 on Friday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma, Inc. has a 1 year low of $2.38 and a 1 year high of $7.80. The stock has a fifty day moving average price of $3.65 and a 200 day moving average price of $4.57. The stock has a market cap of $192.08 million, a price-to-earnings ratio of -1.92 and a beta of 1.37.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. Analysts forecast that Inozyme Pharma, Inc. will post -1.59 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on INZY. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday, November 6th. Raymond James started coverage on Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $12.00 price objective (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus started coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Inozyme Pharma has an average rating of “Buy” and an average price target of $17.00.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.